Correlating efficacy and immunogenicity in malaria vaccine trials. (October 2018)

• Record Type: Journal Article
• Authors: McCall, Matthew B.B.; Kremsner, Peter G.; Mordmüller, Benjamin
• Is Part Of: Seminars in immunology. Volume 39(2018)
• Page Start: 52
• Page End: 64
• Publication Date: 2018-10
• Subjects: Malaria -- Vaccine -- Substitute endpoint -- Immunological correlate -- Immunological surrogate -- Controlled human malaria infection; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2018.08.002
• Languages: English
• ISSNs: 1044-5323

Abstract

Abstract: The availability of an effective and appropriately implemented malaria vaccine would form a crucial cornerstone of public health efforts to fight this disease. Despite many decades of research, however, no malaria vaccine has yet shown satisfactory protective efficacy or been rolled-out. Validated immunological substitute endpoints have the potential to accelerate clinical vaccine development by reducing the required complexity, size, duration and cost of clinical trials. Besides facilitating clinical development of existing vaccine candidates, understanding immunological mechanisms of protection may drive the development of fundamentally new vaccination approaches. In this review we focus on correlates of protection in malaria vaccine development: Does immunogenicity predict malaria vaccine efficacy and why is this question particularly difficult? Have immunological correlates accelerated malaria vaccine development in the past and will they facilitate it in the future? Does Controlled Human Malaria Infection represent a valid model for identifying such immunological correlates, or a correlate of protection against naturally-acquired malaria in itself?